[Megaesophagus] was shown to be related to age, male sex, high BMI, dysphagia, and [other variables] (P<0.05). Clinical trials for the treatment of patients with megaesophagus may be necessary.
Patients with megaesophagus are more likely to have a prior surgical or medical condition, such as malignancy or congenital deformity. The underlying cause of megacolon or malformation of the stomach cannot be determined, but it may be an isolated condition.
There is no conclusive evidence on the efficacy of endoscopic therapy and other non-surgical treatments for megaesophagus. There is, however, some evidence for surgical therapy. In particular, endoscopic dilation and laser ablation have been used. Despite all of this, definitive surgical therapy of megaesophagus remains the treatment for choice by specialists.
The majority of patients who have long-term symptoms have symptoms resolve with the use of proton pump inhibitors, but the risk of relapse is high. Recent findings support ongoing surveillance for symptom evolution and symptom alleviation.
Megaesophagus is an abnormally thickened muscular segment of the oesophageal wall in which a muscular gap can be seen on an upper GI endoscopy. Megaesophagus is not associated with pathological reflux.
The diagnosis of megaesophagus cannot be based on symptoms alone. A high degree of suspicion for megaesophagus is necessary for diagnosing the disorder early and preventing unnecessary investigations, unnecessary treatment and delays to surgery.
The incidence of megaesophagus is low, at around 1 per 100,000 per year. The incidence of megaesophagus remains fairly stable over time and over different age groups. It is most frequently diagnosed in older men with a history of peptic ulcer disease.
No significant results (p < 0.05) were recorded in the frequency of megaesophagus among affected families and control families. This result may be due to the differences in occurrence in the families of some cases and also the small number of cases.
The short myotomy remains a commonly accepted treatment for achalasia, but recent technological advancements have created new treatment options for surgeons and endoscopists with the help of an advanced surgical endoscope.
MME for correction of oesophageal dysmotility does not improve the quality of life of patients at rest and during the day, and has a negative impact on the general health of patients.
Because of the current availability of only one treatment method for megaesophagus, we believe that new treatment methods in this area are very necessary to develop the appropriate type of treatment and to select appropriate candidates for treatment.
Patients treated with short myotomy with either endoscopic or open surgery typically respond well with improvement in cough, pain, and swallowing. The long-term results of these treatments are not clear because of the small sample size and our short follow-up at this time. Despite this study, surgeons and referral centers should continue their experience with short myotomy, because patients seem to have a higher success rate.